TP protein TPn Normalised trial protein VEGF Vascular Endothelial Growth Factor V1 Distribution volume for central compartment of free drug V2 Distribution volume for peripheral compartment of free drug V3 Distribution volume of bound drug (Vb) Vb Volume of distribution of bound drug Vmax Maximum binding capacity Vp Central volume of distribution of free drug (L), Vt Peripheral volume of distribution of free drug Vs Versus VSS Steady state volume of distribution WAM Wald’s approximation method WRES Weighted residuals WT Weight Residual random effect ε Inter-individual random effect η Population mean value of the parameter θ Inter-occasion random effect κ Variance of σ2 ε Variance of φ2 κ Clinical rationale Bristol-Myers Squibb (BMS) Australia Pty Ltd wishes to vary the dosing recommendations for the use of Reyataz (atazanavir) in HIV-infected paediatric patients. In essence the proposal is: To lower the age range from 8 years to 6 years For patients in the weight 15 to 20 kg, to add the new dose of atazanavir/ritonavir (ATV/RTV) 150/100 mg
TP protein TPn Normalised protein VEGF Vascular Endothelial Growth Factor V1 Distribution volume for central compartment of free drug V2 Distribution volume for peripheral compartment of free drug V3 Distribution volume of bound drug (Vb) Vb Volume of distribution of bound drug Vmax Maximum binding capacity Vp Central volume of distribution of free drug (L), Vt Peripheral volume of distribution of free drug Vs Versus VSS Steady state volume of distribution WAM Wald’s approximation method WRES Weighted residuals WT Weight ε Residual random effect η Inter-individual random effect θ Population mean value of the parameter κ Inter-occasion random effect σ2 Variance of ε φ2 Variance of κ Clinical rationale Bristol-Myers Squibb (BMS) Australia Pty Ltd wishes to vary the dosing recommendations for the use of Reyataz (atazanavir) in HIV-infected paediatric patients. In essence the proposal is: To lower the age range from 8 years to 6 years For patients in the weight 15 to 20 kg, to add the new dose of atazanavir/ritonavir (ATV/RTV) 150/100 mg trial
auspar-atazanavir-131021-cer.docx